ReviewFrontiers in immunology2022
Interaction between microbiota and immunity and its implication in colorectal cancer.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Article
- Exploring Risk Factors and Sex Differences in Colorectal Cancer: Insights from Current Evidence.Cells · 2026Review
- The Barrier-Microbiota-Inflammation Axis in Colorectal Cancer: Mechanisms and Emerging Diagnostic & Therapeutic Strategies.Cancers · 2026Review
- Gut microbiome-driven colorectal cancer via immune, metabolic, neural, and endocrine axes reprogramming.NPJ biofilms and microbiomes · 2026Review
- Gut microbiota-innate immune crosstalk in the initiation and progression of CRC: mechanisms and therapeutic potential.Frontiers in immunology · 2026Review
- The impact of gut microbial short-chain fatty acids on colorectal cancer development and prevention.Gut microbes · 2025Review
- The antimicrobial metabolite nisin Z reduces intestinal tumorigenesis and modulates the cecal microbiome in ApcMicrobiology spectrum · 2025Article
- Microbiome of Young and Later-Onset Colorectal Cancer.The Surgical clinics of North America · 2025Review
- The Gut Microbiome and Colorectal Cancer: An Integrative Review of the Underlying Mechanisms.Cell biochemistry and biophysics · 2025Review
- TScience advances · 2025Article
- Gut microbiota influences colorectal cancer through immune cell interactions: a Mendelian randomization study.Discover oncology · 2025Article
- The Immune Environment in Colorectal Adenoma: A Systematic Review.Biomedicines · 2025Review
- 3-O-Acetyl-11-Keto-Oncology research · 2025Article
- Crosstalk Between Oral Microbiome and Cancer: Emerging Trends and Insights.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- Predictors of response to immunotherapy in colorectal cancer.The oncologist · 2024Review
- The Crucial Roles of Diet, Microbiota, and Postbiotics in Colorectal Cancer.Current nutrition reports · 2024Review
- ACE2-dependent and -independent SARS-CoV-2 entries dictate viral replication and inflammatory response during infection.Nature cell biology · 2024Article
- Interaction of human gut microbiota and local immune system in progression of colorectal adenoma (MIMICA-1): a protocol for a prospective, observational cohort study.Frontiers in oncology · 2024Article
- Article
- USP3 plays a critical role in the induction of innate immune tolerance.EMBO reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Colorectal cancer (CRC) is one of the leading causes of cancer-related death in the world. Besides genetic causes, colonic inflammation is one of the major risk factors for CRC development, which is synergistically regulated by multiple components, including innate and adaptive immune cells, cytokine signaling, and microbiota. The complex interaction between CRC and the gut microbiome has emerged as an important area of current CRC research. Metagenomic profiling has identified a number of prominent CRC-associated bacteria that are enriched in CRC patients, linking the microbiota composition to colitis and cancer development. Some microbiota species have been reported to promote colitis and CRC development in preclinical models, while a few others are identified as immune modulators to induce potent protective immunity against colitis and CRC. Mechanistically, microbiota regulates the activation of different immune cell populations, inflammation, and CRC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.